In Asia, on-demand PrEP could be an “economically efficient” way to prevent HIV
Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges
Modelling study backs targeted, not universal, lenacapavir PrEP for pregnancy and breastfeeding
Injectable PrEP in Leeds and London: criteria, approval and continuation
Top 5 stories on threats to the global HIV response from CROI 2026
Top 5 stories on HIV prevention and sexual health from CROI 2026
Major US cohort reveals sharp racial disparities in HIV acquisition among trans women
Home visits and flexible PrEP cut HIV incidence by 70% in rural Kenya and Uganda
